Bausch + Lomb Announces New Scientific Data, Educational Events at the American Academy of Ophthalmology Annual Meeting

VAUGHAN, Ontario, Oct. 15, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and educational events taking place during the American Academy of Ophthalmology (AAO) annual meeting in Chicago, October 18-21, 2024.

Scientific posters will highlight the results of studies evaluating the new enVista® Envy™ full visual range intraocular lens (IOL), the TENEO™ Excimer Laser Platform and VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024%, as well as other technology. Sponsored educational events will focus on Bausch + Lomb products including new Blink® Nutritears™ nutritional supplement, MIEBO® (perfluorohexyloctane ophthalmic solution) and Xiidra® (lifitegrast ophthalmic solution) 5%.

At the Bausch + Lomb exhibit booth (#4826), the company will feature additional new surgical offerings, including ScoutPro®, a point-of-care portable device for precisely measuring tear osmolarity.

Posters

  • “Defocus Curve Performance and Outcomes of Near Activity Vision Questionnaire Following Trifocal IOL Implantation.” Muzychuk et al.
  • “Evaluating Chord Mu as a Predictive Factor Associated with Glare and Halos in a Novel Full Visual Range Trifocal IOL.” Wiley et al.
  • “Long-Term Results of Minimally Invasive Microsclerostomy.” Shultz
  • “Monocular and Binocular VA Outcomes with a Novel Full Visual Range Trifocal IOL or Monofocal IOL.” Shultz et al.
  • “Myopic LASIK Performed Using a Novel Excimer Laser: Outcomes of the Pivotal Trial.” Waring et al.
  • “Outcomes of PROWL and Contrast Sensitivity Following Myopic LASIK Using a Novel Excimer Laser.” Stonecipher et al.
  • “Performance and Safety of Minimally Invasive Nasal Trabeculostomy in OAG.” Grover et al.
  • “Reduction in IOP After Switching to Latanoprostene Bunod in Glaucoma Patients in Real-World Clinical Practice.” Okeke et al.

Special Events

Friday October 18

From Vision to Comfort: Evolving Technologies in IOL & Dry Eye Management

  • 6:30 p.m. CT; Mastro’s, 520 Dearborn Street
  • Speakers: Mitch Shultz, MD, and Mark Milner, MD

Saturday October 19

Industry Showcase Theater: NEW! Blink NutriTears Nutritional Supplement from Bausch + Lomb

  • 9:30-10:00 a.m.; CT McCormick Place Convention Center, South Hall A, Booth #1026
  • Speaker: Laura M. Periman, MD

MIEBO/XIIDRA Industry Showcase Theater: Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition

  • 12:30-1:00 p.m. CT; McCormick Place Convention Center, South Hall A, Booth #1026
  • Speakers: Sheri Rowen, MD, and Lisa Nijm, MD

MIEBO/XIIDRA Industry Showcase Theater: Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition

  • 3:30-4:00 p.m. CT; McCormick Place Convention Center South Hall A, Booth #1026
  • Speakers: Darrell White, MD, and Laura Periman, MD

Innovations in DED & Breakthrough Cataract Surgery Techniques

  • 7:00-9:00 p.m. CT; Venue SIX10, 610 S. Michigan Avenue
  • Speakers: Eric D. Donnenfeld, MD, FAAO, and Timothy Page, MD

Sunday, October 20

Industry Showcase Theater: NEW! Blink NutriTears Nutritional Supplement from Bausch + Lomb

  • 9:30-10:00 a.m. CT; McCormick Place Convention Center, South Hall A, Booth #1026
  • Speaker: Laura M. Periman, MD

MIEBO/XIIDRA Industry Showcase Theater: Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition

  • 12:30-1:00 p.m. CT; McCormick Place Convention Center, South Hall A, Booth #1026
  • Speaker: Francis Mah, MD

###

enVista Envy toric and non-toric IOL Indications and Important Safety Information

Indications

The enVista Envy hydrophobic acrylic IOL is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia with less than or equal to 1.0 D preoperative corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL. 

The enVista Envy toric hydrophobic acrylic IOL is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia and corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL. 

Warnings/Precautions

Physicians should weigh the potential risk/benefit ratio before implanting the enVista Envy lens under any of the circumstances or conditions outlined in the Instructions for Use labeling. Some visual disturbances may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or radial lines around point sources of light (starbursts) under nighttime conditions, glare, double vision, haziness and blurred vision. It is expected that, in a small percentage of patients, the observation of such phenomena will be annoying and may be perceived as a hindrance, particularly in low illumination conditions such as nighttime driving. As with other trifocal IOLs, there is a possibility that visual disturbances may be significant enough that the patient will request explant of the IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients, therefore, patients implanted with trifocal IOLs should exercise caution when driving at night or in low light or poor visibility conditions. Care should be taken to achieve IOL centration as IOL decentration may result in patients experiencing visual disturbances or suboptimal vision under certain lighting conditions. The surgeon must target emmetropia to achieve optimal visual performance. Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning). Please provide a copy of the Patient Information Brochure, which can be found at www.bausch.com/IFU. Posterior capsule opacification (PCO) may significantly affect the vision of patients with multifocal IOLs earlier in its progression than patients with monofocal IOLs. This may be due to the reduced contrast sensitivity observed with multifocal IOLs. 

Additional Precautions for Toric IOLs: The enVista Envy Toric IOL has not been evaluated in a clinical study. In general, astigmatism that is corrected with a higher cylinder power IOL can result in clinically significant residual astigmatism. The effect of residual astigmatism at distance, intermediate, and near was evaluated in a clinical study of patients who had been implanted with non-toric enVista Envy IOLs and were induced with cylinder power to simulate various levels of residual astigmatism. If a secondary surgical intervention is necessary to reposition the IOL, explantation should be considered as some patients may have recurrent or persistent issues related to rotational instability and misalignment.  

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

ATTENTION: See the Directions for Use for a complete listing of indications and important safety information.

Indications and Important Safety Information for Technolas Teneo 317 Model 2 System

Indications for Use. The Technolas Teneo 317 Model 2 is indicated for laser-assisted in situ keratomileusis (LASIK) in: (1) Patients for the reduction or elimination of myopic astigmatism up to -10.00 D MRSE, with sphere between -1.00 D to -10.00 D and cylinder between 0.00 and -3.00 D; (2) Patients who are 22 years of age or older; (3) Patients must have a stable refraction in the last 12 months, as documented by previous clinical recordings, i.e., the spherical and cylindrical portions of the manifest distance refraction have not progressed at a rate of more than 0.50 D per year prior to the baseline examination in the eye(s) to be treated.

WARNING. Danger of injury due to failure to observe the patient selection criteria! Failure to observe the contraindications and potential adverse effects may result in serious permanent patient injury. The usage of the laser system is limited to a specific field of applications. Observe the contraindications and potential adverse effects listed in the User Manual before selecting a patient and starting any treatment.

Contraindications. Contraindications of the Technolas Teneo 317 Model 2 include patients: (1) with any type of active connective tissue disease or autoimmune disease; (2) with signs of keratoconus, abnormal corneal topography, and degenerations of the structure of the cornea (including but not limited to pellucid marginal degeneration); (3) with significant dry eyes (severe Dry Eye Syndrome). If patients have severely dry eyes, LASIK may increase the dryness. This may or may not go away. Severe eye dryness may delay healing of the flap or interfere with the surface of the eye after surgery. It may result in poor vision after LASIK; (4) for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in less than 250µ of residual corneal thickness from corneal endothelium; (5) with uncontrolled diabetes; (6) with uncontrolled glaucoma; (7) with active eye infections or active inflammation: (8) with recent herpes eye infection or problems resulting from past infections; (9) with known sensitivity to medications used for standard LASIK surgery.

Potential Risks and Side Effects: (1) Miscreated flap; (2) Subconjunctival hemorrhage or bleeding; (3) Wrinkles in flap that may require a flap lift; (4) Corneal erosion/abrasion, epithelia defect; (5) Elevated IOP; (6) Debris or foreign body under flap; (7) Epithelial ingrowth under flap; (8) Debilitating visual symptoms, especially at night; (9) Decreased or fluctuating visual acuity; (10) Decreased ability to see in low-light conditions; (11) Light sensitivity; (12) Dry Eye syndrome; (13) Inadequate treatment result; (14) Regression; (15) Corneal damage; (16) Posterior vitreous detachment or retinal detachment, floaters or vascular accidents; (17) Foreign body sensation or pain (initial postoperative days); also, potentially including chronic eye pain that is resistant to therapy referred to as neuropathic pain; (18) Infection/inflammation; (19) CTK (Central Toxic Keratopathy); (20) Medication intolerance; (21) Ptosis; (22) Cataract; (23) Ocular penetration; (24) Potential risk of psychological harm.

This is not all you need to know. Please see the User Manual for a complete list of safety information, including a full list of contraindications, warnings, precautions and risks.

Caution: Federal (U.S.) law restricts this device to sale, by or on the order of a physician. 

Important Safety Information for VYZULTA

Indication

VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

You are encouraged to report negative side e­ffects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for VYZULTA.

Important Safety Information for MIEBO

Indication

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for MIEBO.

Important Safety Information for XIIDRA

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

IMPORTANT SAFETY INFORMATION

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Click here for full Prescribing Information for Xiidra.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

Media Contact:

Caryn Marshall

[email protected]

(908) 493-1381

Investor Contact:

George Gadkowski

[email protected]

(877) 354-3705 (toll free)

(908) 927-0735 

© 2024 Bausch + Lomb.

MTB.0442.USA.24

Back to Press Releases